FGF1 and obesity due to melanocortin 4 receptor deficiency: Together, these data indicate that FGF1 treatment can promote metabolic changes in cancer cells that may sustain their growth and highlight the potential to define FGF1-dependent gene expression signatures that predict endocrine resistance in obesity.